NCT07570485 Feasibility Assessment of Adapted Physical Activity in Patients Treated for a Brain Tumor
| NCT ID | NCT07570485 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Center Eugene Marquis |
| Condition | Brain Tumor Adult |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2026-07-08 |
| Primary Completion | 2028-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2026-07-08 with a primary completion date of 2028-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to assess the feasibility of an adapted physical activity (APA) program in adult patients (≥18 years) with primary brain tumors, regardless of tumor type, grade, treatment stage, or the presence of motor, sensory, attention, concentration, or memory deficits. The main question it aims to answer is: What is the effective adherence rate to an APA program among eligible patients with primary brain tumors? Additional questions include: * What is the observance rate (number of sessions completed, intensity achieved, and duration) during the 3-month supervised APA program? * What is the retention rate (proportion of patients completing the program and continuing APA beyond the initial period)? * What is the impact of APA on quality of life, anxiety-depression, and cancer-related symptoms (measured via QLQ-BN20, HADS, and MFI-20 questionnaires at baseline, 3, and 4 months)? Participants will: * Undergo a 3-month supervised APA program (with possible continuation beyond this period). * Use connected watches to monitor physical activity (if they accept the general conditions of use). * Complete self-questionnaires (IPAQ, BREQ-2, QPP, QLQ-BN20, HADS, MFI-20) at inclusion, 3 months, and 4 months. * Be followed for a total of 4 months after inclusion.
Eligibility Criteria
Inclusion Criteria: * Men or women ≥ 18 years old, * Receiving medical oncology treatment at the CLCC Eugène Marquis, * Diagnosed with a primary brain tumour, regardless of diagnosis, grade or treatment, * Possible motor, sensory, attention, concentration, or memory deficits, * Patients who accept the general terms of use for connected watches * Patients affiliated with or covered by the French social security system, * Patients who have received information and signed informed consent (or their legal representative), Exclusion Criteria: * WHO score ≥ 3 * Comprehension disorders that prevent participation in adapted physical activity * Pregnant or breastfeeding women * Patients without the necessary devices to use a smartwatch (smartphone, tablet or computer), * Patients deprived of liberty, under guardianship, or curatorship, or subject to any other administrative safeguard measure. Patients unable to comply with the study schedule for social, medical, or psychological reasons.
Contact & Investigator
Elodie VAULEON, Dr
PRINCIPAL INVESTIGATOR
Centre de lutte contre le cancer Eugène Marquis
Frequently Asked Questions
Who can join the NCT07570485 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Brain Tumor Adult. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07570485 currently recruiting?
Yes, NCT07570485 is actively recruiting participants. Contact the research team at v.jolaine@rennes.unicancer.fr for enrollment information.
Where is the NCT07570485 trial being conducted?
This trial is being conducted at Rennes, France.
Who is sponsoring the NCT07570485 clinical trial?
NCT07570485 is sponsored by Center Eugene Marquis. The principal investigator is Elodie VAULEON, Dr at Centre de lutte contre le cancer Eugène Marquis. The trial plans to enroll 90 participants.